Growth hormone therapy may increase fracture risk in a pubertal patient with osteogenesis imperfecta.
We describe a patient with osteogenesis imperfecta type 1A who was treated with growth hormone for 9 years. The treatment resulted in a marked improvement in growth velocity, but four fractures occurred during the pubertal period.